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Advisor: Dee Griffin 
Many antibiotics and medications used in the treatment of animals have a 
withdrawal time; residues are a concern for the meat industry. The most recently 
published 2009 USDA-FSIS Residue Program Data Report listed 135,389 Inspector-In-
Charge-Generated (IICG) residue samples from 43,142,500 beef and dairy cattle 
inspected that year at harvest (USDA-FSIS 2009a). Of these samples, 1306 contained 
violative antibiotic residues and 327 violative flunixin meglumine residues. Two classes 
of antimicrobials comprised over half of the documented violative antimicrobial residues 
(beta-lactams that include ceftiofur and sulfa drugs that include sulfadimethoxine). While 
the violative residue rate seems small, violative residues are unacceptable. Management 
of carcasses that contain violative residues is costly to the USDA, the meat packing 
industry, and the producers involved.  
 There is no preharvest or ante-mortem screening test currently available that 
mirrors the antibiotic screening test used by the United States Department of Agriculture 
(USDA) Food Safety and Inspection Service (FSIS) in beef and swine packing plants 
(USDA-FSIS Notice 39-09). Adapting the test currently used by the USDA-FSIS to 
screen for antibiotic residues in tissue or used by the Food and Drug Administration 
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(FDA) to screen for drug residues in milk would make it possible for producers and 
veterinarians to identify or predict livestock that might be considered a high risk for 
containing a violative antibiotic residue in tissue. In addition, there is no preharvest 
screening test currently available to detect violative residue levels of flunixin meglumine 
and ceftiofur in cattle prior to market (Damian, 1997).   
 A simple, cow-side test for the presence of drug residues in live animal fluids 
would provide useful information for tissue drug residue avoidance programs. This work 
describes adaptation and evaluation of rapid screening tests to detect drug residues in 
serum and urine. Medicated herd animals had urine, serum, and tissue biopsy samples 
taken during drug treatment. Samples were tested by rapid methods and high-
performance liquid chromatography (HPLC). The adapted microbial inhibition method, 
kidney inhibition swab (KIS®) test, was useful in detecting sulfadimethoxine in serum 
and successfully predicted proper drug withdrawal in the kidney by HPLC, 5 to 6 days 
post treatment. The lateral flow (LF) screening method for flunixin and beta-lactams 
adapted for urine was useful in predicting flunixin in the liver detected by HPLC, 96 
hours post-treatment. The same adapted methods were not useful to detect ceftiofur in 
serum or urine relative to the recommended tissue withdrawal time after ceftiofur 
treatment. These anti-mortem screening tests demonstrated that the selection of method 
used, and whether urine or serum are tested, will vary based on drug used and should be 
based on animal treatment history if available. The live animal tests demonstrated the 
potential to allow verification that an individual animal is free of drug residues before 
sale for human consumption.  
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Chapter 1 
Introduction 
 The use of antimicrobials and other approved medications in animal production 
for treatment, prevention, or nutritional purposes inevitably results in the presence of 
residues in animal tissue. To protect consumers from exposure to potentially harmful 
compounds or residue levels, the use of these pharmaceuticals demands that simple and 
reliable methods are available to screen for these compounds prior to entry in the food 
chain. A growing concern among consumers and public health authorities on the use and 
presence of antimicrobial compounds in foods demands further improvement of quality 
management programs in animal production.  
The March 2010, Food Safety Inspection Service (FSIS) National Residue 
Program (NRP) for Cattle Audit Report (24601-08-KC), concluded that the national 
residue program was not accomplishing their mission and identified several areas of 
concern that need to be rectified. The FSIS, Environmental Protection Agency (EPA), 
and Food and Drug Administration (FDA) were tasked to work together to find more 
efficient ways to test for residues, and set new acceptable residue levels.  
Residues 
Contaminated meat may contain residues from veterinary drugs, pesticides, and 
heavy metals. A drug residue is any substance that remains in the tissues of an animal 
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that has been treated with that substance. Surveillance programs detect drug residues in 
the small percentage of samples that are being tested. In 2008, FSIS found .003% positive 
residues in the samples that were collected from over 43 million cattle that were 
slaughtered (USDA-FSIS Red Book 2009a). The 135,389 is a biased sample because it’s 
the animals that are railed off and checked by the FSIS veterinarians on the floor. The 
positives in this group would be over represented because animals that have some 
pathologic lesions and are more likely to have been treated with something. Focusing 
sampling on carcasses that are more likely to contain residues makes efficient use of 
limited resources; however, because of the biased sampling estimation of overall 
prevalence is not possible. The residues of veterinary drugs in meat, eggs and milk have 
lead to concerns about possible adverse effects they may have on consumers of these 
foods. 
 Residues are unlike microbiological pathogens such as E. coli, Salmonella, and 
Listeria, which the public readily associates with food safety. Cooking meat properly can 
destroy bacteria, but no amount of cooking will denature a residue completely (USDA-
FSIS Audit Report 24601-08-KC). In some situations, heat may denature the residue into 
metabolites that are even more harmful to the consumer. 
Veterinary Drugs 
 Since the discovery and development of antibiotics, veterinarians and producers 
have used antibiotics and other approved animal medications for the treatment and 
prevention of disease. It is to be expected that the greatest residue problems would be 
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connected to the most commonly used antibiotics and medications for treating cattle. 
Consistent with expectation, according to the USDA-FSIS (Audit Report 24601-08-KC) 
the top ten drugs that lead to illegal residues in cattle from 2005 to 2010 were: Penicillin, 
Flunixin, Sulfadimethoxine, Gentamicin, Ceftiofur, Sulfamethazine, Oxytetracycline, 
Neomycin, Tilmicosin, and Tetracycline. 
Withdrawal Times 
 Approved medications by the U.S. Food and Drug Administration (FDA) are 
labeled for specific species at defined treatment dosages, and by approved routes of 
administration. The withdrawal time, which is printed on the label is defined as the time 
that is required for 99% of the animals in a population (treated according to label 
directions) to have drug residues that are lower than accepted residue levels defined by 
FDA. If any of the parameters that the recommended withdrawal time is based on (i.e. 
species, dosage, or route) change, then a new withdrawal time should be recommended to 
allow adequate drug metabolism and excretion by the patient and minimize unacceptable 
residues.  
Under the Veterinary-Client-Patient relationship, veterinarians may choose to 
treat a patient with an approved product in a different way than is specified on the label; 
however, in doing so they must consider the effect on the withdrawal time and adjust it to 
match circumstances. Failure to follow the recommended withdrawal time period for 
approved animal drugs is the primary cause of violative levels in food (KuKanich, 2005). 
This failure often occurs due to inadequate record keeping, untrained labor, or 
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inappropriate dose or route of administration for the medication. If veterinarians are 
unsure what an appropriate withdrawal time should be, then the Food Animal Residue 
Avoidance and Depletion program (FARAD), located at http://farad.org/ which was 
developed by pharmacologists and toxicologists from the University of California-Davis, 
is available to veterinarians to provide educated guidance and make appropriate 
recommendations for withdrawal times for approved animal drugs used in different 
circumstances. 
Effects of Residues on Human Health 
Although not common, drug residues in meat have been reported to cause adverse 
health effects in people who have toxic or allergic reactions to the specific drug or drug 
metabolites after consumption of the product (Martinez, 2005). The most memorable 
event occurred in December of 2005, when 225 people consumed Mexican beef that had 
residues of clenbuterol, a growth promoter that is now illegal for use. Another human 
illness outbreak also associated with clenbuterol occurred in 1990 in Spain where 125 
people consumed meat from animals treated with implants. In this later incident, some 
illnesses were attributed to the patients eating tissue that was near the implant location; in 
other cases, it was difficult to prove that hormone residues caused the illness. 
If an individual is sensitive to specific medications or metabolites of a medication, 
they may experience an allergic reaction to antibiotic residues. It is estimated that about 
7% of the general population have drug sensitivities to medications (Gomes, 2005). 
Penicillin residues in meat, in particular, have been documented as causing minor allergic 
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reactions when consumed by humans (Raison-Peyron, 2001). However, not all of the 
people with known drug sensitivities to medications experience symptoms when 
consuming meat with residues. This lack of response is likely because residue levels in 
meat are below threshold levels that would induce a hypersensitivity reaction: penicillin 
for example, is cleared rapidly from the blood through the kidneys into the urine. Results 
from the Joint Expert Committee on Food Additives (JECFA) in 1990 indicated that 
penicillin residues in the kidney and liver (as determined by HPLC) were about 100 times 
higher than those in muscle (Paturkar, 2005). 
Justification 
The latest USDA-FSIS Residue Report, which includes data following the FSIS 
changing residue screening procedures, listed 135,389 Inspector-In-Charge-Generated 
(IICG) residue samples from beef and dairy cattle (USDA-FSIS, 2009a [2008 FSIS 
National Residue Program Data]). Of these samples, 1,306 contained violative antibiotic 
residues and 327 violative flunixin meglumine residues. While all residues are of 
concern, two classes of antimicrobials, beta-lactams that include ceftiofur and sulfa drugs 
like sulfadimethoxine, comprise over half of the documented violative antimicrobial 
residues. The IICG samples were selected from the 43,142,500 bovine slaughtered under 
USDA inspection that year. The 135,389 is a biased sample because it’s the animals that 
are railed off and checked by the FSIS veterinarians on the floor. The positives in this 
group would be over represented because they are the animals that have some pathologic 
lesions and are more likely to have been treated with something. Focusing sampling on 
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carcasses that are more likely to contain residues makes efficient use of limited resources; 
however, because of the biased sampling estimation of overall prevalence is not possible. 
While the violative residue rate seems small, any violative residues are 
unacceptable as they are above the tolerances set by FDA and EPA. Management of 
carcasses that contain violative residues is costly to the USDA, the meat packing 
industry, and the producers involved. The costs are associated with losses due to 
carcasses being trimmed or condemned, and the additional work required for retaining 
and testing for residues. Most important may be the loss of consumer confidence in foods 
of animal origin, especially if carcasses with residues are not detected by screening 
programs. 
Objectives 
 The Food and Drug Administration (FDA) has approved the use of the Kidney 
Inhibition Swab (KIS®) test for post-harvest screening for residues in animal tissues at 
slaughter. This project focused on the possibility of using the KIS® test for screening 
tissue and body fluids of the preharvest animal as an affordable option for evaluating 
residue status. 
1. To determine if the Charm KIS® test technologies used by the USDA-FSIS to 
screen bovine kidneys for antibiotic residues will detect antibiotics in cattle 
urine. 
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2. To determine if the Charm Rapid One Step Assay (ROSA) test technologies, 
particularly the FLUBL Flunixin and Beta-lactam test, can be used to detect 
flunixin meglumine, sulfadimethoxine, and ceftiofur in cattle urine. 
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Chapter 2 
Literature Review 
All animal drugs have to be approved by FDA before they can be marketed for 
public use. Receiving FDA approval is a complicated and expensive process, as the drug 
developer must prove that the medication is safe and effective when used at the proposed 
labeled dosage. The New Animal Drug Application (NADA) must include all the 
possible side effects the drug may cause, and show that they can consistently manufacture 
the product with ingredients from safe and reliable sources. If the drug is for food 
animals, then withdrawal times (WDT) must be provided at the labeled dosage to insure 
that the residues in meat, milk, and eggs are below levels safe for human consumption 
http://www.fda.gov/. 
Withdrawal Time 
 Before a drug can be used in a food-producing animal, experiments are conducted 
to provide evidence that the drug residues in animal tissues are below the approved 
maximum residue limit (MRL) after a certain amount of time. The FDA has proposed a 
regression method that would estimate that 99% of the population was below the 
approved MRL in the suggested withdrawal time with a 95% confidence level (Fisch et 
al., 2000). The withdrawal time (WDT) is the time needed after a treatment is completed 
for the tissue concentrations of the drug, or metabolites from the drug, to decrease below 
concentrations that FDA considers safe for human consumption.  
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 The WDT are typically established with small sample sizes (generally less than 30 
animals), which can a limit the determination of adequate times when the percentage of 
acceptable animals with residue is small, such as the 1% limit utilized by FDA. The FDA 
uses a regression approach to estimate a 99th percentile of a population with a 95% 
confidence level. (Concordet et al., 1997). With differences in drug depletion curves, this 
may not always be the best method for determining WDT. The European Union (EU) 
doesn’t think that statistical methods are a sufficient way to evaluate WDT. They 
establish WDT when all tissues from observed animals fall below the acceptable 
minimum residue level (MRL). 
  The most common causes of illegal residues are people ignoring the required 
WDT, poor record keeping that does not allow for identification and tracking of WDT, 
and administration of the wrong drug or the wrong dosage. Administering a drug in an 
extralabel route can result in delayed or incomplete absorption and lead to an increased 
WDT. In addition, the formulation of a drug can affect how long it can be detected in 
certain tissues, consequently changing the WDT (KuKanich et al., 2005).  
 In the U.S., tilmicosin is labeled for a 28 day WDT after receiving a subcutaneous 
dose of 10mg/kg. In a study by KuKanich et al., (2005) the drug was administered to 
cattle, and biopsy samples were taken from the site of injection, muscle, liver, kidney and 
fat at different times to determine the residue depletion time using HPLC. A WDT of 34 
days was established such that all tissues except the subcutaneous injection site were 
below the MRL. This study also showed that administering tilmicosin by extralabel route 
intramuscularly left residues in the muscle samples at injection site for over 56 days. The 
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Europeon Medicines Agency (EMA) recommends that if the target tissue of a drug is 
muscle, then the regulatory authorities should set the WDT on the MRL for muscle (Jiang 
et al., 2006). Differences in testing and regulations for different countries complicate the 
use of antimicrobials, especially in animals that may be slaughtered for other countries. 
 Veterinary drugs that are administered intramuscularly or subcutaneously may 
require additional consideration for residue issues at the site of injection (Reeves et al., 
2007). The quality issue related to injection sites has been addressed by programs like 
Beef Quality Assurance (BQA; http://www.bqa.org), which has helped to reduce 
injection site lesions in beef rumps from 21% in 1991 to 2.1% in 2000 (National Beef 
Quality Audit, 2000). A significant effort to approve subcutaneous labels for many new 
products for cattle has had a large impact on product quality and likely residue. Although 
the industry is making great improvements in quality there is not reliable data for 
exposure to injection site residues at this time.  
Residue tests 
 A good residue-screening test needs to be fast, inexpensive, and sensitive enough 
to detect residues in accordance with the established MRL. Three bacterial inhibition 
tests have been developed by FSIS (http://www.fsis.usda.gov) to screen kidneys from 
food animals at slaughter for residues (Korsrud et al., 1998). There is no screening test 
currently available to detect the MRL’s of all approved drug classes of antibiotics. Every 
test has limitations for specificity, sensitivity, or ease of use at a slaughter facility.  
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 The Swab Test On Premises (STOP) uses tissue that is macerated with the swab, 
the swab is then incubated on medium inoculated with Bacillus subtilis and with a disk 
containing an antibiotic for 16-24 hours (Korsrud et al., 1998). The Calf Antibiotic and 
Sulfa Test (CAST) uses kidney fluid collected by making an incision in the kidney and 
absorbing fluid, placing the collection with Bacillus megaterium in medium and 
incubating for 16-24 hours. For both the STOP and the CAST, a zone of inhibition 
around the swab demonstrates the presence of a microbial inhibitor in the collected 
sample. The Fast Antimicrobial Screen Test (FAST) uses B. megaterium and the same 
medium as the CAST test. However, the medium is supplemented with dextrose and 
bromcresol purple, which allows the bacteria to grow at a faster rate, thus decreasing the 
required incubation time from 16 to 6 hours. None of these approved screening tests in 
the U.S. are sensitive enough to detect chloramphenicol or sulfa drugs. The Live Animal 
Swab Test (LAST) screens urine and plasma antimortem for drug residues. The LAST 
was adapted from STOP assay but using a higher concentration of Bacillus subtilis spores 
in the assay.  
 The Premi Test (Stead et al., 2004) was developed based on bacterial inhibition 
with the growth of Geobacillus stearothermophilus, which is sensitive to several different 
antibiotics (Schneider et al., 2008). The development and validation of the test proves 
that it is capable of detecting multiple sulphonamide residues represented in tissues at 
one-half to one times the MRL. The Premi Test can also distinguish the β-lactams 
successfully. Because the test uses G.stearothermophillus and shows a higher sensitivity 
towards Gram-positive antimicrobial compounds, it does not detect the aminoglycoside 
(gentamincin, lincomycin, neomycin, streptomycin), or the phenicol (chloramphenicol, 
17 
 
thiamphenicol) drug classes. The Premi test is sensitive to the macrolide class. Because 
of the inability to detect some drug classes it is important to be able to distinguish the 
possible drug residues present before testing. 
 Penicillin is the drug most often misused, and a preslaughter test using an easily 
collected body fluid from the treated animal to predict if the residue level is low enough 
for slaughter would be beneficial to the food animal industry. Chiesa et al. (2006) looked 
at animals treated with penicillin and evaluated correlations between kidney tissue 
samples collected by laparoscope, plasma, and urine. They showed a fivefold lower drug 
concentration in plasma compared to kidney tissue. A plasma penicillin concentration of 
<0.4 ng/ml can be used as an indicator with 95% confidence that 99% of all the kidneys 
will be below the accepted MRL at slaughter. The average penicillin in urine was 
approximately 10 times greater than the kidney cortex concentration. A urinary penicillin 
concentration of <140 ng/ml can be used with 95% confidence that 99% of all the 
population will be below MRL at slaughter. 
 Three residue-screening tests, the Four Plate Test (FPT), Screening Test for 
Antibiotic Residues (STAR), and the Premi Test, were compared (Janosova et al., 2008) 
to evaluate their ability to detect 10 different sulphonamides. The MRL is only effective 
if a good screening program is in place. This study showed that the Premi Test was the 
most sensitive to the sulphonamides.  
 The most widely used class of antibiotics is the β-lactams, which include 
penicillins and cephalosporins. Several different residue tests have been developed for 
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analyzing samples that may contain these antibiotics. A simple, rapid, sensitive, and 
specific test has been developed to confirm 10 of the β-lactam antibiotics from bovine 
kidney samples (Fagerquist et al., 2005). Using a solvent extraction, dispersive solid-
phase extraction and liquid chromatography-tandem mass spectrometry (LC/MS/MS) for 
confirmation and quantification. Bovine kidney samples received from FSIS were tested 
for β-lactams. In the 23 samples that were tested with this method, 70% of the β-lactams 
tested positive in samples except for desfuroylceftiofur cysteine disulfide (DCCD), which 
is a metabolite of ceftiofur. The recovery rate for DCCD was 58%.  
 The ideal screening test should give a reliable result close to the MRL level with 
few, if any, number of false positive or negative samples (Schneider et al., 2008). A large 
number of false positives leads to excessive tests to confirm the results, and if no follow-
up testing may lead to monetary loss to the plant or the owner. In contrast, false negative 
tests have the potential for unsafe animal products entering the food supply.  
 A study, done by Schneider et al., (2009) used 235 carcasses that were retained 
during slaughter and sampled by FSIS inspectors. Beef kidney juice, and serum was 
collected to evaluate the FAST, Premi, and KIS® screening tests as well as Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) for residue confirmation. Each 
of the samples was split and tested simultaneously with FAST, Premi, and KIS® 
screening tests. A separate analysis was also done on each sample for aminoglycosides 
and other antibiotics using LC-MS/MS. The screening tests were easy to perform, and the 
FAST test was easy to read with zones of inhibition (Korsrud et al., 1998). However, the 
color changes in Premi and KIS® tests were sometimes difficult to interpret. Most of the 
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carcasses sampled (196 out of 235) were negative for any antibiotic residues. All three of 
the screening tests detected 2 samples with dihydrostreptomycin, and the Premi and KIS® 
tests detected a sample with sulfamethazine while the FAST did not. LC-MS/MS 
detected 3 antibiotics with no U.S. FDA approved tolerance listed for beef cattle. The 
Premi test found a sample with gentamicin and kanamycin in serum, however none of the 
screening tests detected these antibiotics in kidney juice.  
 This study demonstrates that no specific test currently available is reliable at 
detecting all antibiotics at MRL (Schneider et al., 2009). The KIS® and Premi both had a 
number of false positives in both the kidney juice and serum samples, which increases 
laboratory testing requirements and expense. In the case of mixtures of antibiotics, LC-
MS/MS showed an advantage in identification and quantitation. The serum samples were 
variable in this study, which related to the hydration status of the animal with shipping. 
Serum may be less variable for antemortem screening on the farm in most consistently 
hydrated animals. 
Approximately one third of the 9.15 million dairy cows in the U.S. are 
slaughtered annually, which makes up about 18% of U.S. ground beef (USDA-FSIS 
Audit Report 24601-08-KC). Cull dairy cows and veal calves are the most high-risk 
animal groups to contain violative residues. When an animal tests positive with a KIS® 
test in a slaughter plant, samples of liver, muscle, and kidney are shipped frozen to the 
FSIS Technical Support Laboratory to determine the type and amount of drug residue 
present. 
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 Ceftiofur (Payne et al., 2004) which is used to treat cattle for respiratory disease, 
foot rot, and mastitis is rapidly converted to desfuroylceftiofur and desfuroylceftiofur 
related metabolites. The parent compound is not detected in milk or tissue. Payne et al., 
2004 evaluated the regulatory concern that the ceftiofur metabolites were being 
incorrectly identified during rapid screening tests. HPLC was used to detect ceftiofur 
metabolites in dairy cattle. A high and low dose group of dairy cows were treated and 
slaughtered following recommended withdrawal times. Liver, kidney, and diaphragmatic 
muscle was collected and analyzed for ceftiofur and metabolites. The kidney residues 
were considerably higher than liver or muscle. Most false positive tests were from kidney 
or liver samples, which had been frozen for shipment and then thawed for analysis. 
Screening assays were run on frozen samples, so the effect of freezing cannot be 
compared at this time. Future research to evaluate the cause of false positives in frozen 
samples could be valuable. The false positive effect was not present in diaphragm tissue. 
Four laboratories compared samples of swine and bovine kidney and muscle and 
bovine milk (Hornish et al., 2003). The sample results were relatively consistent across 
samples. The methods were reliable for detection and quantitation of ceftiofur and its 
related metabolites in all samples. 
Microbial inhibition tests are usually used for detecting antibiotic residues 
because they are easy to run and inexpensive. In looking at the development of different 
tests over the years, it is hard to comparatively evaluate them based on published 
literature alone because different tissues, tests, and procedures are used. Chemical tests 
have been considered too specific and expensive for screening but HPLC is capable of 
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detecting multiple antibiotics and is cost effective when considering the savings of 
forwarding samples and waiting for results (Pikkemaat et al., 2009). There is still a need 
for a quality-screening test to detect residues in slaughter facilities. 
 Gentamicin is an effective and inexpensive antibiotic for treating gram-negative 
bacterial infections in humans. Most of the antibiotic is rapidly metabolized and 
eliminated from the animal in the first 48 hours, but for gentamicin a small residue 
remains in the kidney cortex for months making it unacceptable for use in fed cattle or 
dairy animals. The Chiesa et al., (2006), study looked at blood and urine samples taken 
from steers that received three doses of 4 mg/kg gentamicin given intramuscularly on the 
same day. Kidney tissue was also collected by laproscopic surgery as well as at slaughter. 
The plasma levels of gentamicin were not detectable by day 3 post-treatment, but the 
urine samples remained positive for 75 days before the concentration declined to an 
undetectable level. The correlation between urine and kidney tissue suggested a 
relationship of 1:100. Therefore, a test that is sensitive enough to detect urine gentamicin 
concentration of 1 ng/ml is equivalent to a 100 ng/g concentration in for kidney tissue.  
Flunixin Meglumine 
 Flunixin meglamine was originally labeled for horses in the U.S. and had limited 
residue data for use in food animals. However, flunixin is now approved for food 
animals. The FARAD recommends a WDT of 72 hours for milk, and 10 days for meat 
after intramuscular injection with the data collected for Flunixin. (Damian et al., 1997) 
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 The use of NSAIDs can improve an animal’s outcome to a disease. A survey 
(Kopcha et al., 1992) of 2000 food animal veterinarians in the United States found that 
93% used NSAID, with 57% of them having used a NSAID more than once a week. 
Flunixin meglamine is the most commonly used, although none of them are approved for 
food animal use. Approximately 88% of the veterinarians said when they used an NSAID 
with an antibiotic, the recommended withdrawal time for meat and milk was based on the 
antibiotic withdrawal time. The potential for residue is small when flunixin is used with 
an antibiotic.  
Flunixin has been approved for use in non-lactating cattle by intravenous 
injection. The FDA has a withdrawal time of 4 days for meat (KuKanich et al., 2005). 
FARAD recommends an extralabel milk withdrawal of 72 hours and a meat withdrawal 
of 4 days based on published milk residue depletion studies. Flunixin causes excessive 
injection site lesions so it is not recommended for the product to be given intramuscularly 
or subcutaneously due to inflammatory response and increased WDT (Haskell et al., 
2003). Administering flunixin intramuscularly causes tissue damage, inflammation, and 
slow or incomplete absorption, which can result in illegal residues.  
The FDA has approved 1.1 to 2.2 mg/kg of flunixin given intravenously and 
WDT of 4 days for meat and WDT of 36 hours for milk (Smith et al., 2008). The 
American Medicinal Drug Use Clarification Act (AMDUCA) does not consider 
convenience of administration an acceptable reason for extralabel use of a drug. Cattle 
producers are not necessarily skilled at giving medications intravenously. Administering 
flunixin intramuscularly is very irritating to tissue and increases creatinine kinase from 
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baseline levels of 86 U/L to 136 U/L. Because of the tissue irritation, FARAD has 
recommended a WDT of 30 days for meat when flunixin is administered intramuscularly. 
There is limited data for subcutaneous administration of flunixin so a WDT has not been 
established. FARAD recommends an 8-day WDT for meat with oral administration and 
48 hours WDT for milk. However, flunixin granules or paste are not protected under 
AMDUCA rules so only approved formulations should be used in cattle.  
Flunixin is considered a drug with high regulatory concern because of the 
common extralabel routes of administration people use in cattle. Producers should follow 
label directions if possible. If an extralabel route is used an extended WDT should be 
recommended for meat and milk. 
Ceftiofur 
 Ceftiofur is an antibiotic with broad-spectrum use that can be used to treat 
respiratory disease in cattle. It has a low level of toxicity and does not have a withdrawal 
time following treatment. After injection, it is converted into free and protein bound 
metabolites. These metabolites have antimicrobial activity and can be detected by residue 
tests. It is important to be able to distinguish between this β-lactam, which has no residue. 
At this time, there is no maximum residue limit for ceftiofur metabolites in tissues in the 
U.S. (Moats et al., 1998). 
There are various screening tests to detect residues in animal tissues. The USDA-
FSIS uses a 7-plate assay test, but some antibiotics are more difficult to detect. 
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Penicillinase is used in all but one of the plates to detect the β-lactam antibiotics from 
other drug classes. The β-lactam antibiotics, which include the cephalosporins, are 
resistant to degradation from penicllinase so they are not identified by this residue-
screening test. They can be degraded by other β-lactamases. A chromatographic 
procedure has been developed to identify different penicillins in tissues, but it cannot 
identify the cephalosporins or their metabolites in tissues. 
 The two cepahalosporins currently approved for use in food animals in the U.S. 
are ceftiofur and cephapirin (Moats et al., 1998). The metabolites of these antibiotics can 
be identified by rapid screening assays. 
Chapter 3 
Development and Model Testing of Ante-Mortem Screening 
Methodology to Predict Prescribed Drug Withholds in Heifers 
ABSTRACT 
A simple, cow-side test for the presence of drug residues in live animal fluids would 
provide useful information for tissue drug residue avoidance programs. This work 
describes adaptation and evaluation of rapid screening tests to detect drug residues in 
serum and urine. Medicated heifers had urine, serum, and tissue biopsy samples taken 
while on drug treatment. Samples were tested by rapid methods and high-performance 
liquid chromatography (HPLC). The adapted microbial inhibition method, kidney 
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inhibition swab (KIS®) test, was useful in detecting sulfadimethoxine in serum and its 
response correlated with the prescribed withdrawal time for the drug, 5 to 6 days post 
treatment. The lateral flow (LF) screening method for flunixin and beta-lactams, adapted 
for urine, was useful in predicting flunixin in liver detected by HPLC, 96 hours post 
treatment. The same adapted methods were not useful to detect ceftiofur in serum or 
urine due to a lack of sensitivity at the levels of interest. These ante-mortem screening 
test studies demonstrated that the method selected, and the sampling matrix chosen (urine 
or serum), will depend on the drug used and should be based on animal treatment history 
if available. The live animal tests demonstrated the potential for verification that an 
individual animal is free of drug residues before sale for human consumption.  
Many antibiotics and medications used in animal treatment have a withdrawal 
time established by the U.S. FDA to ensure that drug residues, a concern for the meat 
industry, do not exceed the set tolerance levels. The most recently published 2009 
USDA-FSIS Residue Program Data Report listed 135,389 Inspector-In-Charge-
Generated (IICG) residue samples from 43,142,500 beef and dairy cattle inspected that 
year at harvest (19, 20). Of these samples, 1306 contained violative antimicrobial 
residues and 327 violative flunixin residues (19). Two classes of antimicrobials 
comprised over half of the documented violative antimicrobial residues (beta-lactams, 
including ceftiofur and sulfa drugs, such as sulfadimethoxine). While the violative 
residue rate seems small, violative residues are unacceptable. Management of carcasses 
that contain violative residues is costly to the USDA, the meat packing industry, and the 
producers involved. Most important may be the loss of consumer confidence in foods of 
animal origin. A simple pre-harvest, cow-side test to verify the presence of violative drug 
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residues in live animal fluids would provide useful information for avoiding drug 
residues in tissues before the animal is sold for human consumption.  
In October 2009, the USDA-FSIS selected Charm Science Inc. Kidney Inhibition 
Swab (KIS®) test as the antibiotic residue screening test for ruminants in U.S. packing 
plants (17, 18). KIS® test sensitivity in spiked swine tissue extracts were reported in 2004 
(13). In 2009, the method was re-evaluated with beef and swine using drug spiked swabs; 
the results are shown in Table 1 and compared to tissue tolerances.  
Testing live animal fluids by adapting antibiotic screening methods such as the 
KIS® test, used by the USDA-FSIS for antibiotic residue screening in beef and swine 
processing plants (1,4), or the related DelvotestTM, used by the U.S. Food and Drug 
Association (FDA) to screen for beta-lactam drug residues in milk, would make it 
possible for producers and veterinarians to identify or predict livestock that might be 
considered a high risk for containing a violative antibiotic residue in tissue (6, 8, 9). In 
addition, there is no preharvest inhibition-based screening test currently available to 
detect violative residue levels of flunixin and beta lactams such as ceftiofur in cattle prior 
to market (14). Some inhibitory methods for detecting drug residues have been 
demonstrated effective in serum (15, 16); however data that correlates serum and urine 
detection to tissue tolerance levels is limited. Randecker et al. evaluated serum and urine 
as predictor of sulfadimethoxine in swine tissues in 1987 (9). Chiesa et al. evaluated 
correlations between kidney tissue concentrations and urine or plasma that would lead to 
the development of rapid screening tests for penicillin (3). Evaluation of Geobacillus 
stearothermophilus-based screening tests, such as the KIS® test, for their ability to predict 
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violative levels of drug residues in ante-mortem animal urine and serum samples prior to 
harvest could provide a tremendous benefit to the industry. 
MATERIALS AND METHODS 
 Animals and procedures. All animal procedures were reviewed and approved by 
the U.S. Meat Animal Research Center (USMARC) Animal Care and Use Committee. 
Blood, urine and tissue samples. All animals were housed on center at the 
USMARC Feedlot and procedures were performed under veterinary guidance. A 
preliminary study utilized twelve feedlot heifers to test all the collection and laboratory 
procedures. A larger study later involved twelve heifers in each of the three treatment 
groups and the control group. The heifers weighed between 340-430 kg, were fed a corn-
based finishing ration and had not received any antibiotic treatment for the previous 60 
days. Heifers were randomly assigned to the experimental groups. Urine and blood were 
collected from each animal before administration of their assigned medication (Day 0). 
The heifers were weighed and treatment groups received ceftiofur sodium (2.2 mg/kg 
BW, IM), sulfadimethoxine (55 mg/kg BW, IV), or flunixin meglamine (2.2 ml/kg BW, 
IV). Twenty-four hours after administration, urine and blood was collected from each 
animal. In addition, 24 h post-treatment a renal biopsy was collected from control heifers 
and heifers receiving ceftiofur by a peri-cervical approach with a 4 mm biopsy punch. At 
24 h post-treatment for the heifers that received flunixin meglumin and the control group, 
a liver biopsy was performed between the 10th and 11th ribs using a 4 mm biopsy punch. 
On day 4 of the study, a renal biopsy was collected as described above from heifers 
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treated with sulfadimethoxine and the control group. Urine and serum was collected 
every 24 hours up to 24 hours past the FDA-approved medication withdrawal time for 
each treatment drug At the prescribed withdrawal time for each treatment, urine and 
blood were again collected from each heifer. Each of the serum and urine samples were 
split and tested at both USMARC and at Charm Sciences Inc. for comparison and 
confirmation of results.  
KIS® test modifications. All urine and serum samples were examined by each of 
the following two minor modifications of the KIS® test. No significant differences in 
results were obtained between the two modifications. 
Modification I: (USMARC, Clay Center, NE). Serum samples were centrifuged 
(1600 x g, 10 min). A sample of urine or serum (500 µl) was combined with a KIS® urine 
tablet in a microtube. The microtube was capped and vortexed (10 s), inverted to ensure 
tablet was dissolved, and vortexed again (10 s). A KIS® swab absorbed the mixture and 
was incubated for 4 hours at 30º C. All urine samples were tested similarly without 
sample centrifugation. 
 Modification II: (Charm Sciences, Inc., Lawrence, MA). Serum samples were 
pre-centrifuged (1200 x g, 3 min) and supernatant (100 µl) was added to a 
buffering/nutrient tablet (Charm Sciences, Inc.). The mixture was dissolved for 30 
minutes, absorbed onto a KIS® swab and incubated (4 h) at 30º C. Urine samples were 
tested similarly with no sample pre-centrifugation.  
29 
 
Flunixin and beta-lactam (FLUBL) lateral flow (LF) modification. Urine and 
pre-centrifuged serum samples were tested using a modified lateral flow test, LF-FLUBL 
(Charm Sciences Inc.) approved for screening raw milk in the U.S. (5, 14). Samples (100 
µl) were used to rehydrate a LF-urine/serum tablet (Charm Sciences Inc.). A sample 
extraction swab (Charm Sciences Inc.) adapted for kidney testing, consisting of a 
sampling swab and 750 µl buffer, was used to absorb the tablet mixture into the swab and 
dilute into the buffer. Extract buffer (300 µl) was added to the LF-FLUBL test strip and 
the test was performed and results read in a ROSA reader (Charm Sciences Inc.) 
according to instructions for testing milk and kidney (5). 
High Performance Liquid Chromatography (HPLC). HPLC system consisted 
of a Waters Alliance HT (Waters 2795; Waters Corporation, Milford, MA) liquid 
chromatography system equipped with a diode array multiple wavelength detector 
(Waters 996) and a Shimadzu column oven (CTO-10AS VP; Shimadzu America, 
Columbia, MD) set at 30°C for all sample analysis. Sulfadimethoxine analysis was 
performed using a Phenomenex Gemini 5µ C18 110A, 250 x 4.6 mm column. HPLC for 
sulfadimethoxine followed the method of Primus et al. (11). Urine and serum, 1 ml 
volume, were substituted in the method to yield limit of detection (LOD) of 250 ppb for 
serum and 500 ppb for urine. Ceftiofur analysis was performed using a Thermo Scientific 
Hypersil BDS C-18, 250 x 4.6 mm column (Waltham, MA). HPLC for ceftiofur was 
performed following a Desfuroyl Ceftiofur Acetate (DCA) derivative quantitation 
method (6). The method was adapted by substituting 1ml serum or urine for the milk 
portion in the procedure to yield LOD of 5 ppb. Flunixin analysis was performed using a 
Phenomenex Hypersil 5µ ODS (C18; Phenomenex, Torrance, CA), 120A, 250 x 4.6 mm 
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column. Flunixin in serum and urine was analyzed by method developed by Königsson et 
al. and had an LOD 20 ppb (7). Flunixin glucuronide metabolite in urine only was 
detected by hydrolysis to free flunixin by strong base and addition of β-glucuronidase (2) 
and the product was analyzed flunixin as described (7), except samples were frozen at -
80°C instead of -20°C. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS). All tissue 
biopsies were forwarded to the USDA- Agriculture Research Service (ARS) Eastern 
Regional Research Center for LC-MS/MS analysis. Biopsy samples were frozen and 
transferred to a small mortar and pestle and manually ground in the presence of 80/20 
acetonitrile/water (4 mL), along with sufficient internal standard [sulfadoxine (USP) for 
sulfadimethoxine analysis, and flunixin-d3 (Toronto Research Chemicals, Toronto) for 
flunixin analysis] to provide the desired level (500 ppb for sulfadoxine, 100 ppb for 
flunixin-d3). The resultant mixture was tranferred to a disposable 15 mL tube and 
centrifuged (3716 x g, 5 min), after which the supernatant was decanted into a disposable 
centrifuge tube containing C-18 sorbent. After vortex mixing (15 s) and centrifugation, a 
portion (3.0 mL) of the supernatant was transferred to a glass tube and evaporated to <0.5 
mL volume using a Turbovap LV (Zymark, Hopkinton, MA) under stream of N2 at 40°C. 
After addition of water to 0.5 mL, samples were mixed and transferred to a PVDF filter 
vial (0.2 µm, Thomson, Oceanside, CA) for LC-MS/MS analysis. 
 LC-MS/MS instrumentation and chromatography column used have been 
previously described, along with general MS parameters, except for use of 100 ms dwell 
time (21). Mobile phases were 0.1% formic acid in water (A) and 0.1% formic acid in 
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acetonitrile (B). Gradient elution was employed (80% A - 0% A, 10 min). After an 
additional 1 min at 0% A, the column was re-equilibrated to intial conditions (6 min). 
Flow rate was 400 µL/min. Specific analyte MS parameters were as follows: sulfadoxine 
transitions monitored: m/z 310.9-156.0 and 310.9-92.0, declustering potential (DP): 46 V, 
focusing potential (FP): 170 V, collision energy (CE): 25 V and 43 V, collision cell exit 
potential (CXP): 12 V and 8 V; sulfadimethoxine transitions monitored: m/z 311.0-156.0 
and 311.0-108.1, DP: 36 V, FP: 160 V, CE: 29 V and 43 V, CXP: 12 V and 8 V; flunixin 
transitions monitored: m/z 297.0-278.9 and 297.0-263.9, DP: 36 V, FP: 110 V, CE: 33 V 
and 47 V, CXP: 16 V and 16 V; flunixin-d3 transitions monitored: m/z 300.1-282.1 and 
300.1-264.0, DP: 36 V, FP: 140 V, CE: 31 V and 45V, CXP: 26 V and 24 V. 
Quantification of analytes utilized matrix matched calibration curves. 
RESULTS AND DISCUSSION 
 Urine and serum incurred samples were analyzed by HPLC in order to establish a 
concentration for the analytes in these matrices. Ceftiofur incurred serum and urine 
samples were then also analyzed by the KIS® and LF assays, flunixin incurred samples 
were analyzed by the LF assay, and sulfadimethoxine incurred samples were analyzed by 
the KIS® assay. A small scale preliminary dosing study was conducted to test the 
experimental procedures. In the preliminary study, ceftiofur-dosed heifers provided urine 
and serum samples that were negative at all time periods in the KIS® and LF assays. 
Development of LF assay continued to try to improve the limit of detection for the 
second study. Preliminary study results for flunixin and sulfadimethoxine were 
comparable to the main study and reported here. 
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Ceftiofur incurred serum and urine analysis results for the main study are shown 
in Table 2. Levels of ceftiofur in these samples as measured by HPLC ranged from 154-
3680 ppb in urine and 207-1280 ppb in serum (24 h) to <_5 ppb (LOD) at the 
intramuscular or subcutaneous injection WDT (96 h). The KIS® and LF assay results for 
these samples are also indicated in Table 2. One can see that the KIS® results ranged 
from 7/12 positive in urine and 2/12 positive in serum (24 h) to 0 KIS® positive samples 
at 96 h. The LF results ranged from 10/12 positive in urine and 6/12 positive in serum (24 
h) to 0 LF positive samples at 96 h. 
The observed trend in assay response is generally what is desired, and all samples were 
negative at the WDT; however, a fundamental problem is that the tolerance is 400 ppb in 
kidney, and the KIS® and LF LOD is 600 ppb in kidney and serum. Thus, neither test will 
likely be sensitive enough to detect violative samples corresponding to the range of 400-
600 ppb in tissue. Furthermore, the levels in urine and serum may very well be lower than 
in kidney, and thus, more difficult to detect. 
Flunixin incurred serum and urine analysis results for the main study are shown in 
Table 3. Levels of flunixin in these samples as measured by HPLC ranged from 290-1940 
ppb in urine, with lower levels in serum (30-830 ppb, and 6/12 samples <20 ppb) at 24 h. 
At the 96 h withdrawal time, flunixin levels in urine and serum as measured by HPLC 
were < LOD with the exception of 3 urine samples (30-70 ppb).  
  As a NSAID, flunixin will not be detected by an antibiotic inhibition assay such 
as KIS®. Thus, an important part of this study was to develop a live animal screen for 
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flunixin. The LF assay was investigated, and results for the flunixin incurred urine and 
samples are indicated in Table 3. At 24 h, all urine samples were LF positive. The 
maximum dilution which still produced a positive LF assay result was 1:25 for 2 urine 
samples, and 1:50 for the remaining 10 urine samples. As the LOD for the LF assay is 30 
ppb in both urine and serum, the urine dilution range for a negative result corresponds to 
a range estimate of >750 ppb and >1500 ppb, respectively for these urine samples. At 24 
hr, all serum samples were also LF assay positive for flunixin. The maximum dilution 
which gave a positive LF assay result was 1:25 for 4 serum samples, while the remaining 
8 samples required no dilution. This corresponds to an estimate of >750 ppb and >30 ppb 
flunixin for these serum samples, respectively. At the 96 h required WDT, all urine and 
serum samples were negative for flunixin using the LF assay, as would be desired for 
samples expected to be below tolerance levels at that time. In data not reflected in Table 
3, the modified LF method with multiple replicates of the untreated animal samples had a 
false positive result that was more frequent with serum samples (8%) than in urine 
samples (>4%). 
The tissue biopsy results taken from livers at 24 hours are shown in Table 4 
compared to the LF estimates of ppb and HPLC quantified urine samples. Urine, as 
opposed to serum, was selected as the comparator in this table because of the higher 
detected levels of drug and the longer clearance times that were consistent with the 
prescribed tissue withholding time. There were 4 liver samples that exceeded tissue 
tolerances of 125 ppb and the remaining samples had detectable levels ranging from 24-
76 ppb. The recommended animal withhold time of IM flunixin is 4 days and these 24 h 
results would indicate that the liver levels should be well below tolerance after 3 
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additional days withheld. The drop in detectable urine levels at 48 h compared to 24 h 
support that there is a rapid clearing of the drug from the animals.  
As the second most detected drug in IICG samples (18), a flunixin assay must be 
used concurrently with the KIS® assay for antibiotics to be detected with such a high 
frequency in national sampling programs. Urine, as opposed to serum, testing using 
modified-LF at the 1:50 dilution was useful in predicting flunixin levels above and below 
liver tolerance of 125 ppb. The method was cross-reactive to the major urine metabolite, 
flunixin-glucuronide, and therefore detected 75% of samples as positive at 24 h with the 
KIS® test, when 33% of the samples exceeded tolerance in the liver biopsy. At 48 h, 2 
days earlier than the recommended tissue withhold, the 1:50 dilution passed all samples 
as negative, but the undiluted urine samples were still 75% positive indicating urine may 
be useful to detect proper drug withhold time. At 48 h withhold, there was a significant 
reduction in the detected urine levels of flunixin-glucuronide that should correlate to a 
significant reduction in flunixin in tissue. More research is needed to make this 
determination. The 72-h and 96-h urine samples were 50% positive by LF undiluted 
assay, when the recommended withhold time of this drug treatment is 96 h. This indicates 
that the screening method may be useful to identify treated animals up to their withhold 
time even though the LF by the higher dilution of 1:25 or 1:50 is more predictive of 
volatile tissue levels, 
Data from the main study for sulfadimethoxine is shown in Table 5. Levels of 
sulfadimethoxine in urine samples as measured by HPLC ranged from 40 to 11,100 ppb 
in urine at 24 h, with 8/12 of these samples responding negatively in the KIS® assay. 
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These levels dropped off rapidly in urine, and at 48 h, all samples tested negative by 
KIS®. Sulfadimethoxine residues in serum were present at much higher levels than in 
urine, ranging from 44,300 to 139,000 ppb by HPLC at 24 h, and with all samples at this 
time being positive by KIS®. LC-MS/MS of biopsy samples taken 4 days post-dosing 
show that kidney levels generally exceeded 100 ppb tolerance. The higher kidney SDM 
levels on day 4 correlated with KIS® serum test positive results on days 4, 5 and 6. KIS® 
test serum negative results occurred at 96 h with kidney LC-MS/MS levels of 150 ppb, 99 
ppb, and 302 ppb. 
The KIS® test was very useful to correlate the detection of sulfadimethoxine in 
tissue when serum, but not urine, was used as the live animal predictive sample. Serum 
samples were still positive on day 4 when tissue biopsy samples were taken and support 
that the tissue were exceeding tolerance. Urine samples, however, tested negative after 
the initial 24 h and would not be useful in predicting sulfadimethoxine in tissue. It is 
interesting to note that kidney biopsies taken on day 4 (just 24 h prior to the 
recommended WDT of 5 days) from the heifers receiving SDM were still well above the 
100 ppb approved drug tolerance level set forward by the FDA see Table 5. Several of 
the animals tested on day 5 and 6, post-withhold time, were still serum positive for 
sulfadimethoxine. This suggests that the KIS® serum method, which had 25% of serum 
samples on day 6 test positive, could either be erring on the side of safety in predicting 
tissue above tolerance or that the tissues were in fact still exceeding tolerance. More 
research is needed to make this determination. 
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In conclusion, results from this study show that ante-mortem testing of animal 
fluids as a predictor of tissue residue is dependent on the drug with which the animal is 
treated. Residues of sulfadimethoxine in tissue were able to be predicted with serum, but 
not urine, when tested using an inhibition test like the KIS® test. Residues of the anti-
inflammatory drug flunixin were able to be predicted with a LF method of urine samples, 
but not serum samples. Neither serum nor urine was useful in detecting ceftiofur residues 
due to the method’s insensitivity to levels achieved in serum and urine. Further drug 
studies are needed to understand the drug residue relationships between tissue, urine, and 
serum to develop future pre-harvest screening tests. 
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Table 1- KIS® test sensitivity determined from beef and swine kidney spiked swabs after 
sampling compared to Tissue Tolerances (T=tissue, K=kidney, L=liver) 
Antibiotic Drug KIS® Detection Level 
(ppb) 
U.S. Tolerance@ 
(ppb) 
Penicillin G 30-40 50 T 
Ampicillin 100 10 T 
Amoxicillin 100 10 T 
Cloxacillin 300 10 T 
Ceftiofur* 4000 400 K 
250 K (swine) 
Cephapirin* 100 100 T 
Sulfamethazine 500 100 K 
Sulfadimethoxine 250 100 K 
Sulfathiazole 250 100 K 
Oxytetracycline 3000 12000 K 
Chlortetracycline 12000 12000 
Tetracycline 1000 12000 
Tylosin 400 100 K 
Erythromycin 500 100 T 
Pirlimicin* 1000 500cow L 
Tilmicosin 2500 100 T 
7500 L (swine)  
1200 L (bovine)  
Tulathromycin* 400 3000 K 
Neomycin 1000 7200 K 
Gentamicin 750 400 K 
Streptomycin 10000 2000 K 
Dihydrostreptomycin 2000-4000 2000 K 
Floramphenicol 10000 2500 L (swine)  
3500 L (bovine) 
Chloramphenicol 50000 - 
Enrofloxacin 25000 100 L (bovine) 
Ciprofloxacin 25000 - 
Spectinomycin 10000 4000 K 
Novobiocin 5000 1000 T 
Trimethoprim 1000 - 
Virginiamycin 25000 400 K (swine) 
Bacitracin^ 10000 500 T 
* Drugs known to metabolize into multiple forms. Spiked drug sensitivity may not accurately 
reflect incurred drug level.  
^ mIU/ml 
@
 Tolerance from http://ecfr.gpoaccess.gov/cgi/t/text/text-
idx?c=ecfr&sid=044c20ff4bcde0eaf632fb124f3bdbcf&rgn=div6&view=text&node=21:6.0.1.1.1
6.2&idno=21 
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Table 2- Second incurred ceftiofur study showing HPLC determined part per billion (ppb) ceftiofur at sampling internalsa  
Animal 
ID# 
Urine Samples (ppb) Serum Samples (ppb) 
0 hb 24 h 48 h 72 h 96 h 0 h  24 h 48 h 72 h 96 h 
2956 nd 154 (K+, L+) 198 433 nd nd 375 (L+) 110 (L+) 110 nd 
2962 nd 679 (L+) 183 (L+) 28 nd nd 1008 (L+) 162 12 nd 
2983 nd (K+) 1607 (L+) 147 48 nd nd 207 101 21 nd 
2996 nd 1006 (L+) 216 67 nd nd 744 (L+) 202 15 (K+, L+) nsc 
3009 nd 1475 (L+) 151 79 nd nd 833 (K+, L+) 249 34 nd 
3011 nd 339 (K+) ns (K+) ns (K+) ns nd (L+) 576 (L+) ns ns ns 
3033 nd (L+) 718 (K+) ns 38 nd nd 819 131 15 nd 
3041 nd 676 (K+, L+) 488 (L+) 23 nd nd 381 345 46 nd 
3141 nd 2331 (K+, L+) 49 30 nd nd 997 (K+, L+) 272 24 9 
3198 nd 419 (L+) 551 (L+) 27 nd nd 631 135 13 ns 
3262 nd 3680 (K+, L+) 75 30 nd nd 620 93 33 nd 
3951 nd 332 (K+, L+) 167 47 nd nd 1280 237 42 nd 
a
 K+, KIS positive; L+, lateral flow positive; ND, not detected by HPLC analysis (<5 ppb LOD); NS, no sample for HPLC analysis. 
bBefore treatment with ceftiofur sodium at 2.2 mg/kg of body weight, intramuscularly. 
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Table 3- Second incurred flunixin study showing HPLC determined ppb at sampling internalsa  
Animal 
ID# 
Urine Samples (ppb) Serum Samples (ppb) 
0 hb 24 h 48 h 72 h 96 h 0 h 24 h 48 h 72 h 96 h 
2928 nd 1010 (L+,50)c 340 (L+) 160 (L+,10) nd (L+) nd 830 (L+,25) 680 (L+,10) nd nd 
2959 nd 790 (L+,25) 30 (L+) nd nd (L+) nd nd (L+) nd nd nd 
2961 nd 1270 (L+,50) 100 (L+,25) 50 (L+,10) 30 nd 160 (L+,25) nd nd nd 
2989 nd 1460 (L+,50) 80 (L+,10) 260 (L+) 70 (L+,10) nd 30 (L+) nd nd nd 
2990 nd 740 (L+,50) 240 nd nd nd nd (L+) nd nd nd 
3007 nd 340 (L+,50) 60 nd nd nd nd (L+) nd nd nd 
3023 nd 1120 (L+,50) 30 nd nd nd nd (L+) nd nd nd 
3024 nd 1550 (L+,50) 120 (L+,10) 60 (L+) nd (L+) nd 70 (L+) nd nd nd 
3044 nd 290 (L+,25) ns (L+) ns ns nd nd (L+) nd nd nd 
3153 nd 1770 (L+,50) 220 (L+,10) 30 (L+) 50 (L+) nd 380 (L+,25) 130 (L+,25)  nd nd 
3227 nd 380 (L+,50) 110 (L+,10) 30 nd nd nd (L+,25) nd nd nd 
3995 nd 1940 (L+,50) 70 (L+) 60 (L+) nd (L+) nd 40 (L+) nd nd nd 
aL+, laeral flow positive; noted with maximum-fold dilution of sample providing a laeral flow positive response; ND, not detected by 
HPLC analysis (<20 ppb LOD); NS, no sample for HPLC analysis. 
bBefore treatment with flunixin meglamine at 2.2 ml/kg of body weight, intravenously. 
cDilution used to generate a positive response is noted where appropriate: 50 = 1:50, 25 = 1:25, 10 = 1:10, and no number = undiluted 
sample. 
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Table 4- Second incurred flunixin study showing urine screening and HPLC flunixin-glucuronide 
concentrations (ppb) at 24 and 48 hours compared to LC-MS-MS flunixin (ppb) of 24 hour liver 
biopsy sample 
  
Animal 
ID# 
24 h Post-Treatment 48 h Post-Treatment 
Liver  
LC-MS-MS 
(ppb)a 
Urine  
LF Screen 
(ppb)b 
Urine 
Modified-HPLC  
(ppb) 
Urine  
LF Screen 
(ppb)b 
Urine 
Modified-HPLC  
(ppb) 
2928 74 >1500 1010 30-300 340 
2959 24 750-1500 790 30-150 30 
2961 45 1500-3000 1270 >750 100 
2989 187 >1500 1460 300-750 80 
2990 47 >1500 740 <30 240 
3007 56 >1500 340 <30 60 
3023 60 >1500 1120 <30 30 
3024 54 >1500 1550 300-750 120 
3044 33 750-1500 290 >30 ndc 
3153 247 >1500 1770 300-750 220 
3227 165 >1500 380 >300 110 
3995 150 >1500 1940 >30 70 
aLC-MS/MS liver samples greater than 125 ppb are violative tissue residue. 
bLOD of screen = 30 ppb multiplied by largest dilution for positive. 
cND, not detected. 
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Table 5: Sulfadimethoxine determined in urine and serum samples by HPLC from second dosing of heifers compared with LC-
MS/MS of kidney biopsy take at 96 ha  
 
Animal 
ID# 
Urine Samples  
(ppb) 
Serum Samples  
(ppb) 
Kidney 
(ppb) 
 0 hb 24 h 48 h 72 h 96 h 120 h 144 h  0 h 24 h 48 h 72 h 96 h 120 h 144 h 96 h 
79 nd 9500 (K+) 300 300 nd nd nd nd 100000 (K+) 18200 (K+) 4000 1600 (K+) 1000 300 176 
2903 nd 700 100 nd 500 nd nd nd 51000 (K+) 15600 (K+) 4000 (K+) 1900 500 200 150 
2940 nd 7000 (K+) 700 4000 300 200 nd nd 75000 (K+) 24000 (K+) 10200 (K+) 2800 (K+) 900 200 nsc 
2953 nd 760 nd nd nd nd nd nd 49400 (K+) 14700 (K+) 5200 (K+) 1600 (K+) 300 200 252 
2957 nd 11100 (K+) 600 nd 400 ns nd nd 65300 (K+) 19600 (K+) 12200 (K+) 4100 (K+) 1000 (K+) 1300 389 
2960 nd 5000 (K+) nd nd nd nd nd nd 85200 (K+) 21000 (K+) 9000 (K+) 4800 (K+) 3200 (K+) 2200 (K+) 384 
2968 nd 2100 (K+) nd 100 nd 100 nd nd 139000 (K+) 24900 (K+) 9600 (K+) 3000 1400 (K+) 800 302 
2980 nd 11100 (K+) 600 1500 40 nd nd nd 48200 (K+) 14000 (K+) 5000 (K+) 4700 (K+) 700 650 ns 
3034 nd 40 nd nd nd nd nd nd 45000 (K+) 15500 (K+) 5000 (K+) 1300 (K+) 700 200 161 
3184 nd 1000 nd nd nd nd nd nd 44300 (K+) 11500 (K+) 2900 (K+) 700 300 300 99 
3913 nd 1000 (K+) nd nd nd nd nd nd 67100 (K+) 22600 (K+) 12000 (K+) 4900 (K+) 3400 (K+) 2200 (K+) 852 
3916 nd 5000 (K+) 2200 1300 4200 (K+) 100 nd nd 83500 (K+) 30700 (K+) 12200 (K+) 5200 (K+) 2600 (K+) 1500 (K+) 804 
aK+, KIS positive; ND, not detected (urine LOD < 500 ppb and serum LOD < 200 ppb for the HPLC methods used); NS, no sample for 
HPLC analysis. 
bBefore predose intravenous treatment of 55 mg/kg of body weight. 
 
 
 
46 
 
Chapter 4 
Conclusion 
National Residue Program 
 FSIS administers the National Residue Program to ensure that our food supply is 
safe from veterinary drugs, pesticides, and heavy metals. FSIS works in collaboration 
with the EPA and FDA. The FDA is responsible for approving drugs for food producing 
animals and setting the acceptable levels of residues in edible tissue. The EPA is 
responsible for setting the acceptable levels of pesticides in food producing animals. The 
FSIS will collect and test suspect animals for residues and follow the guidelines set forth 
by the FDA and EPA. 
 The FSIS has two sampling plans. One plan is a scheduled sampling plan, which 
involves randomly sampling carcasses that have been approved for consumption to 
determine the prevalence of residues in our food supply. The second plan is an inspector 
generated plan where the inspector will select carcasses based on several factors which 
include: 1) signs or symptoms noted in the live animal inspection; 2) pathological 
conditions or abnormalities found in the carcass; 3) previously documented residue 
violations by the animal’s owner; 4) herd history; and 5) animal identified as a “high 
risk” type such as dairy or bob veal. 
FSIS publishes the “National Residue Program Scheduled Sampling Plans (the 
Blue Book), and the “National Residue Program Data” (the Red Book) annually to report 
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the testing results for the national residue program that would have been completed the 
previous year. 
Program Concerns 
 The March 2010 Audit Report (USDA-FSIS 24601-08-KC) revealed several 
important limitations in the current National Residue Program. In fact, the first finding 
states that the FSIS and other responsible agencies need to re-establish the program to 
accomplish the mission. Coordination between the FSIS, EPA, and FDA has not been 
working to communicate and resolve issues without the Surveillance Advisory Team 
(SAT), and the Interagency Residue Control Group (IRCG) acting as forums for their 
communication. 
 The audit report also concluded that more residues need to be tested. The EPA 
requests that the FSIS test for 23 different types of pesticides, of which FSIS tests only a 
few. FSIS argues that EPA has not provided a list of those with acceptable tolerances 
such that the test results, even if performed, would be useless. In 2008, FSIS ranked 23 
pesticides in the annual sampling plan but tested for only one of the pesticides (USDA-
FSIS 2009b). With the limited laboratory resources available for the testing program, 
FSIS has also stated that if they start testing for additional pesticides they will have to 
decrease the amount of samples they are currently taking for Salmonella and Shiga-
toxigenic E. coli to accomplish the task. 
 The FSIS and FDA need to improve testing methods. When a drug is submitted to 
the FDA for approval, the drug company submits the testing method as part of the new 
drug application. Once the product is approved, FSIS must follow the testing method 
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when confirming the presence of residues in meat. Unfortunately, the approved test may 
not be the best test. FSIS has requested FDA to assist them in evaluating new methods for 
use in testing. This is called “bridging”, and although the FDA indicated they were 
willing to help FSIS with this issue, they have worked for over two years to bridge 
penicillin and it is still not done. FSIS has requested that ceftiofur be bridged but FDA 
has stated that it would be too difficult to bridge this antibiotic, which is one of the top 
residues found in cattle to date. If the U.S. would move forward to the European Union 
system of performance-based testing, new technology could be implemented immediately 
resolving this testing issue. 
 Tolerances have not been set by the EPA for many pesticides and heavy metals. 
Consequently, should the FSIS test for one of them they have no idea what is acceptable 
and no authority to retain the meat in question. In 2008, the Mexican government rejected 
a load of meat from the U.S. with levels of copper that exceeds their tolerance levels. 
Since copper does not have an established tolerance level in the United States, FSIS had 
no basis to stop the distribution of this meat to Americans. As another example, in 2008 a 
vigilant cattle producer reported that his cattle had ingested arsenic. The cattle were held 
until testing could be completed, but if the producer had not identified this situation the 
meat would have also been distributed. 
 Results from testing need to be available in a more realistic period. By the time 
FSIS publishes the Red Book it can be up to 12 months after the results were last 
received. This delay appears to be a due to bookkeeping procedures where testing results 
have to be manually analyzed and consolidated, taking scientists and staff an excessive 
amount of time in preparing and editing results for the Red Book. Moving to a more 
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efficient electronic means of testing and doing away with the current system of hand 
writing would provide usable information in a timely fashion for all agencies.  
 Efficiency in identifying animals with barcodes instead of retained tags is also a 
concern because the retained tags are issued as a group of four. However, FSIS inspectors 
often need to identify at least six pieces of carcass so they improvise with other methods 
of labeling. These other methods are not consistent, and are often difficult to read and 
follow throughout the testing process. A better barcode labeling system that could rapidly 
and consistently label all required pieces of carcass that needed to be retained for testing 
is needed. 
Conclusions 
There is currently not a simple cow-side test for the presence of drug residues in 
live animal fluids that would provide verification that an animal is free of drug residues 
before it is sold for slaughter. Identifying animals with residues before they are sold 
would help eliminate the possibility of them entering the food chain. 
FSIS is changing their sampling plans to test fewer samples for more residues. 
This response to the audit performed in 2010 is a positive step forward in making meat 
safer for consumers.  
The research project we did at USMARC showed higher levels of 
sulfadimethoxine in 30% of the heifers that were treated at label recommendations within 
24 hours of WDT ending. The rate at which animals metabolize pharmaceuticals varies 
and the statistical methods that we currently use have different rates of success for 
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different products. More research needs to be done to address this complex issue facing 
animal agriculture. 
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